| Typicality: | 0.276 |
| Saliency: | 0.267 |
| in preclinical tumour models | 4 | location |
| to single-agent ibrutinib | 2 | transitive-object |
| in the same 40:1 ratio | 2 | other |
| combination → shown → efficacy | 5 |
| combination → show → efficacy | 3 |
| combination → demonstrate → efficacy | 3 |
| negative | neutral | positive |
| 0.058 | 0.287 | 0.655 |
| Raw frequency | 11 |
| Normalized frequency | 0.267 |
| Modifier score | 0.500 |
| Perplexity | 185.024 |